Tsung-Tien Wu1, Ya-Hsin Kung. 1. 1 Department of Ophthalmology, Kaohsiung Veterans General Hospital , Kaohsiung, Taiwan, Republic of China .
Abstract
PURPOSE: To evaluate the 2-year outcome, efficacy, and safety of intravitreal ranibizumab injections for myopic choroidal neovascularization (CNV). METHODS: We retrospectively reviewed the medical records of 28 consecutive eyes that received intravitreal injections of ranibizumab for myopic CNV with a 24-month follow-up. Retreatment was performed as needed in eyes with persistent or recurrent CNV. Patient demographic data, best-corrected visual acuity (BCVA), CNV findings on fluorescent angiography, central macular thickness on optical coherence tomography, total number of treatments, and complications were recorded. RESULTS: Mean baseline BCVA was 0.53±0.32 logMAR [Snellen equivalent (SE), 6/20], and improved significantly to 0.28±0.32 logMAR (SE, 6/11) at 1 year and 0.29±0.28 logMAR (SE, 6/12) at 2 years (both P<0.01, Wilcoxon signed-rank test). The average number of total injections over 2 years was 3.32 (SD 2.13). A mean of 2.82 injections were performed in the first year, and 0.50 in the second year. Twenty-three eyes (82.1%) had no need for treatment during the second year of follow-up. Mean improvement from the baseline was 2.57 Snellen lines (SD 2.35) at 1 year, and 2.29 lines (SD 2.69) at 2 years. At 2 years, 11 eyes (39.3%) showed a gain of at least 3 lines after treatment. No complications were noted after treatment. CONCLUSIONS: Intravitreal ranibizumab injection was safe and effective in treating myopic CNV, with visual improvement maintained over 2 years.
PURPOSE: To evaluate the 2-year outcome, efficacy, and safety of intravitreal ranibizumab injections for myopic choroidal neovascularization (CNV). METHODS: We retrospectively reviewed the medical records of 28 consecutive eyes that received intravitreal injections of ranibizumab for myopic CNV with a 24-month follow-up. Retreatment was performed as needed in eyes with persistent or recurrent CNV. Patient demographic data, best-corrected visual acuity (BCVA), CNV findings on fluorescent angiography, central macular thickness on optical coherence tomography, total number of treatments, and complications were recorded. RESULTS: Mean baseline BCVA was 0.53±0.32 logMAR [Snellen equivalent (SE), 6/20], and improved significantly to 0.28±0.32 logMAR (SE, 6/11) at 1 year and 0.29±0.28 logMAR (SE, 6/12) at 2 years (both P<0.01, Wilcoxon signed-rank test). The average number of total injections over 2 years was 3.32 (SD 2.13). A mean of 2.82 injections were performed in the first year, and 0.50 in the second year. Twenty-three eyes (82.1%) had no need for treatment during the second year of follow-up. Mean improvement from the baseline was 2.57 Snellen lines (SD 2.35) at 1 year, and 2.29 lines (SD 2.69) at 2 years. At 2 years, 11 eyes (39.3%) showed a gain of at least 3 lines after treatment. No complications were noted after treatment. CONCLUSIONS: Intravitreal ranibizumab injection was safe and effective in treating myopic CNV, with visual improvement maintained over 2 years.